Teva Pharmaceutical Industries LimitedTEVANYSE
Loading
R&D Expense Growth Under PressureDecelerating
Percentile Rank62
3Y CAGR-40.1%
5Y CAGR-38.3%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
-40.1%/yr
Quarterly compound
5Y CAGR
-38.3%/yr
Consistent
Percentile
P62
Within normal range
vs 5Y Ago
0.1x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | 4.30% |
| Q3 2025 | 4.92% |
| Q2 2025 | -1.21% |
| Q1 2025 | -8.86% |
| Q4 2024 | 12.92% |
| Q3 2024 | -10.78% |
| Q2 2024 | 11.16% |
| Q1 2024 | 3.42% |
| Q4 2023 | -7.51% |
| Q3 2023 | -8.00% |
| Q2 2023 | 8.70% |
| Q1 2023 | 20.48% |
| Q4 2022 | 20.00% |
| Q3 2022 | -23.25% |
| Q2 2022 | 1.33% |
| Q1 2022 | -7.79% |
| Q4 2021 | 9.91% |
| Q3 2021 | -10.48% |
| Q2 2021 | -2.36% |
| Q1 2021 | -33.51% |
| Q4 2020 | 48.06% |
| Q3 2020 | 14.67% |
| Q2 2020 | 1.81% |
| Q1 2020 | -40.91% |
| Q4 2019 | 55.83% |
| Q3 2019 | -13.04% |
| Q2 2019 | 5.75% |
| Q1 2019 | -11.53% |
| Q4 2018 | -5.14% |
| Q3 2018 | 7.24% |
| Q2 2018 | -8.52% |
| Q1 2018 | -11.94% |
| Q4 2017 | -33.94% |
| Q3 2017 | 12.14% |
| Q2 2017 | 6.35% |
| Q1 2017 | -33.19% |
| Q4 2016 | 3.17% |
| Q3 2016 | 76.80% |
| Q2 2016 | -3.60% |
| Q1 2016 | -12.78% |